Protek to begin supplies of generic Ozempic to Russian market

Protek, one of Russia's leading pharmaceutical distributors, will begin the supplies of an Ozempic (semaglutide) generic, originated by Danish diabetes care and obesity giant Novo Nordisk (NOV: N) against diabetes mellitus to the Russian market by the end of this year, reports The Pharma Letter’s local correspondent.

Denis Krasilnikov, Protek's deputy general director for commerce said in an interview with the Russian Vedomosti business paper, the new drug is known as Kvinsenta and is produced by the Russian drugmaker Promomed. It is planned, it will be supplied both to Russian pharmaceutical retail a and state customers.

Over the first 10 months of 2023, total sales of Ozempic in the Russian market decreased year-on-year basis by 70% to 718 million roubles ($78 million). According to data of the Russian analyst agency DSM Group, in packages sales of the drug fell by 76% to 73,136 units.